Twenty-six of the 29 patients in the safety population enrolled by the 18 October 2021 data cutoff, with RET fusion–positive solid tumors excluding RET fusion–positive NSCLC or thyroid cancer, were enrolled by the efficacy enrollment cutoff date of 18 February 2021. The gene discussed is RET; the disease is non-small cell lung carcinoma.